I find that the cash ($146M) vs valuation (55M) is rocket fuel for “the herd”. Also presenting itself as an “undiscovered gem” may contribute to a good ol’ pop. They have good social media skills and their website is gorgeous. Being that this will be about as much DD as the masses ever do it can and most times is quite important for fueling said pop. RSI in the...
Based on my research, I think that the $3 strike price expiring July 15, with the price of $0.21 or lower is what I would pick right now. As you know, the OTM options can be profitable even if they don`t reach the strike price. If the stock moves closer to the strike price after you enter the trade, or if there is a rapid increase in Implied Volatility, you can...
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib,...
ZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
AGEN hasn't done this in years...what? It hasn't sustained these levels for any meaningful amount of time. I did a quick fib retracement using those 2017 highs as the upper anchor and you can see what has revealed itself. The 236 area is a key pivot. Most of the time it has acted as a resistance pivot. But, so far AGEN has held these levels. Where does it go from...
LTRN is a stranger to high volume. For the last 2 quarters, it hasn't traded more than 355k shares on a GOOD day. Many days even see less than 100k shares trade. The current OS on it is 11 M suggesting the float is, at the very most, 11 million as of the last reported OS. This morning the company announced FDA news and was granted Orphan Drug Designation for its...
Took the chart back out to March of last year to do a little fib retracement. Wouldn't you know, CLVS has been channel bound for a minute between the 618 and 786 fib lines with pretty clear support and resistance levels at each. Since it retraced back to the 786 again and is holding (for now), volume is likely going to be the "friend" or "foe" depending on how...
CLVS Clovis Oncology is sitting at a strong support area ready for a bounce. My Price target is the 10usd resistance level On 5/5/2021 HC Wainwright brokerage Lowered the Price Target for CLVS Clovis Oncology to Buy Rating from $13.00 to$12.00
There’s no reason in the world that a biopharmaceutical company like $ONTX that operates cancer research and has a very good quarterly should be stationary at the same price, rather lower than the time at which the quarterly report was submitted, which was excellent and above the expectations of the analyses. After a vertical takeoff he retracted his full price...
Look for weekly close above 37
Siearr is struggling with both 10SMA and 20SMA. It may go back to $8.62. It is a strong support though. If it breaks down, short.
the beta is high with this one
Ignore the day to day... focus on the end game. It's a perfect setup.
We have a triple rejection of the sub 8.60 price range on the weekly candles, setup doesn't get much better than that. Consolidation has taken longer than expected but what else is new haha.
I think we will see a sharp move this month. From reading the chart alone I am wagering it's going to be a bullish move... even though the fundamentals of the company are up for debate.
BerGenBio OSL:BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The stock is currently in a short term uptrend that could provide a new test of important resistance, where a...